sEphB4-HSA

also known as Recombinant EphB4-HSA Fusion Protein · soluble EphB4-human serum albumin

Protein / enzyme biologic targets EFNB2, EPHB4 via inhibition

Developed for: head and neck squamous cell carcinoma · acute myeloid leukemia · non-small cell lung carcinoma · urothelial carcinoma · bladder carcinoma in situ · bladder transitional cell carcinoma · cancer of unknown primary site · castration-resistant prostate carcinoma
+15 more
· cholangiocarcinoma · chronic myelomonocytic leukemia · gallbladder carcinoma · infiltrating bladder urothelial carcinoma · Kaposi's sarcoma · metastatic carcinoma in the bone · metastatic prostate carcinoma · myelodysplastic syndrome · pancreatic adenocarcinoma · prostate adenocarcinoma · prostate cancer · prostate carcinoma · renal cell carcinoma · T-cell acute lymphoblastic leukemia · urinary bladder carcinoma
Investigated by: National Cancer Institute (NCI) · University of Southern California · Vasgene Therapeutics, Inc · Northwestern University · The V Foundation for Cancer Research · University of Colorado, Denver
+1 more
· Whittier Foundation

Trials 13

today NCT06493552 · Ph 2/3 NCT03552796 · Ph 1 NCT03993106 · Ph 2 NCT04486781 · Ph 2 NCT04091867 · Ph 1 NCT04033432 · Ph 2 NCT03519984 · Ph 1 NCT03146871 · Ph 2 NCT03049618 · Ph 2 NCT02717156 · Ph 2 NCT02767921 · Ph 1 NCT02495896 · Ph 1 NCT01642342 · Ph 1

201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT03552796	Aug 2023 → Aug 2024	bladder carcinoma in situ	University of Southern California	Withdrawn	No outcome recorded
Phase 1	NCT04091867	Jan 2020 → May 2021	head and neck squamous cell carcinoma	University of Colorado, Denver	Completed	No outcome recorded
Phase 1	NCT03519984	May 2018 → Nov 2020	Philadelphia-positive myelogenous leukemia, T-cell acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +1	University of Southern California	Terminated	No outcome recorded
Phase 1	NCT02767921	Aug 2016 → Jan 2020	infiltrating bladder urothelial carcinoma, prostate carcinoma, renal cell carcinoma	University of Southern California	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02495896	Sep 2015 → Apr 2021 overdue	cholangiocarcinoma, gallbladder carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma +1	University of Southern California	Active not recruiting	No outcome recorded
Phase 1	NCT01642342	Sep 2012 → May 2019	cancer of unknown primary site	University of Southern California	Terminated	No outcome recorded Stop: Business
Phase 26 trials · 1 missed
Phase 2	NCT03993106	Sep 2020 → Dec 2024	Kaposi's sarcoma	Vasgene Therapeutics, Inc	Unknown	No outcome recorded
Phase 2	NCT04486781	Aug 2020 → Dec 2025	urothelial carcinoma	Vasgene Therapeutics, Inc	Unknown	No outcome recorded
Phase 2	NCT04033432	Sep 2019 → Feb 2021	castration-resistant prostate carcinoma, hypogonadism, male, metastatic carcinoma in the bone, metastatic prostate carcinoma +1	Northwestern University	Unknown	Missed primary
Phase 2	NCT03146871	Apr 2017 → Mar 2019	acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome	University of Southern California	Terminated	No outcome recorded Stop: Business
Phase 2	NCT03049618	Mar 2017 → Sep 2024	head and neck squamous cell carcinoma, non-small cell lung carcinoma	University of Southern California	Completed	No outcome recorded
Phase 2	NCT02717156	Nov 2016 → Dec 2027 expected	bladder transitional cell carcinoma, prostate cancer	University of Southern California	Active not recruiting	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT06493552	Mar 2025 → Sep 2029 expected	urinary bladder carcinoma, urothelial carcinoma	Vasgene Therapeutics, Inc	Recruiting	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

Field	Value	Cited text
Known as	sEphB4-HSA	“This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein (sEphB4-HSA), and to see how well it works in treating participants with...” NCT03552796 ↗ 10 “In this phase II trial, patients with metastatic urothelial carcinoma that recurred or progressed after platinum-based chemotherapy received soluble EphB4-human serum albumin...” PMID 35984996 ↗ Aug 2022 “Blocking the EphB4-EphrinB2 pathway, which can be accomplished by soluble EphB4 conjugated to human serum albumin (sEphB4-HSA), promotes cell death in preclinical models of...” PMID 36210299 ↗ Sep 2022 “II. To bank specimens for future correlative biomarker studies based on the results of ongoing biomarkers analyses in the phase I of sEphB4-HSA as a single agent.” NCT02767921 ↗ “To document the safety and tolerability of sEphB4-HSA (recombinant ephB4-HSA fusion protein) intravenously (IV) weekly” NCT02495896 ↗ “Determine the unique toxicities of the combination of pembrolizumab and sEphB4-HSA.” NCT03049618 ↗ NCT03993106 ↗ NCT06493552 ↗ NCT01642342 ↗ NCT04486781 ↗ NCT04091867 ↗
Known as	Recombinant EphB4-HSA Fusion Protein	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03146871 ↗ 2 NCT03519984 ↗ NCT03552796 ↗
Known as	soluble EphB4-human serum albumin	“In this phase II trial, patients with metastatic urothelial carcinoma that recurred or progressed after platinum-based chemotherapy received soluble EphB4-human serum albumin...” PMID 35984996 ↗ Aug 2022
Action	Inhibit	“blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor” NCT01642342 ↗
Modality	Protein / enzyme biologic	“recombinant albumin fusion protein” NCT01642342 ↗
Route	Intravenous	“recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes” NCT01642342 ↗
Target	EFNB2	“The expression of sEphB4-HSA target EphrinB2 was correlated with outcomes.” PMID 35984996 ↗ Aug 2022